All News

The possibility that contraceptives are more likely to fail in obese patients is only one reason why you need to take a different tack when counseling them about their most appropriate birth control options. . .

Recently I had the honor to serve as Acting Chair of a Food and Drug Administration (FDA) advisory committee meeting called to provide advice to the Agency on the creation of new guidelines to improve manufacturer-sponsored clinical trials for hormonal contraceptive (HC) agents. . .

I truly believe that "Protocols for High-Risk Pregnancies" has contributed to improving perinatal care.

True precocious puberty differs from premature adrenarche and premature thelarche. Understanding normal sexual development and these common variants will help ob/gyns make the correct diagnosis and appropriate referrals.

No firm relationship exists between folate intake or blood folate levels and breast cancer risk, according to a recent meta-analysis of prospective and case–control studies on the subject, but discrepancy exists in the findings.

It's never too late to quit smoking when it comes to bone density, according to a recent prospective study of postmenopausal women. And it doesn't take long for benefits to begin to accrue.

The answer appears to be "no," according to the results of a recent observational study.

Women who stop taking alendronate after 5 years do not seem to be at any greater risk for fractures than women who continue treatment, but they do seem to experience a moderate decline in bone mineral density (BMD) and a gradual rise in chemical markers associated with fractures.

Call systems for practicing obstetricians vary widely, with many obstetricians being on call for long hours and most lacking recovery periods after being on call, according to the results of a Wisconsin study published in the January issue of the American Journal of Obstetrics & Gynecology.

Repeating bone mineral density (BMD) scans among postmenopausal women reveals little new information that is helpful in predicting fractures, according to a report in the Jan. 22 issue of the Archives of Internal Medicine.

Children who had nuchal translucency thickening during the first trimester, but a normal karyotype and no structural abnormalities, are clinically and developmentally normal during the first 2 years of life, according to a study in the January issue of the American Journal of Obstetrics & Gynecology.

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

Good morning. Thank you very much for showing up at this time of morning. I’m astounded at the number of people here, the buzz. It’s terrific. I think Karen emphasized the importance of pelvic floor support.

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

Questions this month have been answered by:Harvey S. Marchbein, MD, FACOG, FACS, OBGYN.net Osteoporosis Chairman and Editorial Advisor Paul D. Burstein, MD, FACOG, OBGYN.net Osteoporosis Editorial Advisor

Q: Is the treatment for Osteoporosis different for males than females? I am a 67 year old male. Recently by x-rays of my back, it was stated in the report that I have osteoporosis . In a phone conversation with my primary physician's assistant, he stated that I should be on hormones, but that he would have to run it by the primary physician. Since that time, and this was at thanksgiving, I have tried to make contact, by phone to the primary physician. I was told, by office personnel, that I should make an appointment to discuss the situation. My question is, why is it necessary to discuss treatment face to face? Can't he advise me by phone? What is necessary? My schedule is very irregular and also why the extra expense for an office visit just to say here is what you do and if a prescription is necessary, can't he call it in as has been done on other occasions. I would like to know also, isn't it rather uncommon for a male to have this condition? Could you tell me what is the usual treatment in this kind of situation?

ICSI (intracytoplasmic sperm injection) is arguably the biggest advance in assisted reproductive technology since the successful birth of Louise Brown, 21 years ago.

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

OBGYN.net Conference CoverageFrom the 11th World Congress on Human Reproduction, June 2002

OBGYN.net Conference CoverageFrom the 11th World Congress on Human Reproduction, June 2002

OBGYN.net Conference CoverageFrom the 11th World Congress on Human Reproduction, June 2002

OBGYN.net Conference CoverageFrom the 11th World Congress on Human Reproduction, June 2002

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

The First World Congress On: Controversies in Obstetrics, Gynecology & InfertilityPrague, Czech Republic - 1999

A prospective study involving a cohort of over 100,000 female registered nurses from the Nurses' Health Study II finds that women who are infertile due to ovulatory disorders are about 25% less likely to develop breast cancer than women who report no fertility problems (covariate-adjusted hazard ratio 0.75; 95% CI, 0.59-0.96).

We need to remember that screening is screening; it's great, but not perfect.

With as many as 9 out of 10 menstruating women reporting some premenstrual moody blues, what criteria do you use to differentiate mild PMS from severe PMS from premenstrual dysphoric disorder? And what treatments are effective?